{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urinary+Symptoms&page=8",
    "query": {
      "condition": "Urinary Symptoms",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 1457,
    "total_pages": 146,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urinary+Symptoms&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urinary+Symptoms&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T07:01:13.836Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07218380",
      "title": "A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Transitional Cell",
        "Urinary Bladder Neoplasms",
        "Neoplasm Metastasis"
      ],
      "interventions": [
        {
          "name": "Vepugratinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "EV",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 450,
      "start_date": "2025-12-12",
      "completion_date": "2033-05",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-11-19T07:01:13.836Z",
      "location_count": 64,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 48 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07218380"
    },
    {
      "nct_id": "NCT04066894",
      "title": "Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Low Anterior Resection Syndrome",
        "Malignant Anal Neoplasm",
        "Malignant Bladder Neoplasm",
        "Malignant Cervical Neoplasm",
        "Malignant Ovarian Neoplasm",
        "Malignant Pelvic Neoplasm",
        "Malignant Prostate Neoplasm",
        "Malignant Uterine Neoplasm",
        "Malignant Vaginal Neoplasm",
        "Malignant Vulvar Neoplasm",
        "Rectal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Explantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Sacral Nerve Stimulator",
          "type": "DEVICE"
        },
        {
          "name": "Sacral Nerve Stimulator Battery",
          "type": "DEVICE"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2019-04-12",
      "completion_date": "2022-09-01",
      "has_results": true,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-11-19T07:01:13.836Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • Sugar Land, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Sugar Land",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04066894"
    },
    {
      "nct_id": "NCT02070042",
      "title": "Oxybutynin and Omega-3 for OAB (Overactive Bladder)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "Omega 3 Fatty Acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TriHealth Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 85 Years · Female only"
      },
      "enrollment_count": 31,
      "start_date": "2014-02",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2018-01-31",
      "last_synced_at": "2026-11-19T07:01:13.836Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02070042"
    },
    {
      "nct_id": "NCT07277413",
      "title": "A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "NSCLC Adenocarcinoma",
        "Gastroesophageal Cancer (GC)",
        "Gastric Adenocarcinoma",
        "Adenocarcinoma of Esophagus",
        "Squamous Cell Car. - Esophagus",
        "Urothelial Carcinoma (UC)",
        "Bladder Cancer",
        "Mesothelioma",
        "Pleural Mesothelioma",
        "Peritoneal Mesothelioma",
        "Non-Small Cell Lung Cancer NSCLC",
        "Pancreatic Cancer",
        "Biliary Tract Carcinoma"
      ],
      "interventions": [
        {
          "name": "IDE892",
          "type": "DRUG"
        },
        {
          "name": "IDE397",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IDEAYA Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 260,
      "start_date": "2026-03-04",
      "completion_date": "2028-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-16",
      "last_synced_at": "2026-11-19T07:01:13.836Z",
      "location_count": 23,
      "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Duarte, California + 19 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07277413"
    },
    {
      "nct_id": "NCT03017170",
      "title": "Evaluation of the Effect of Dried Cranberry Powder in Women With Dry OAB",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "Dried Cranberry",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 100 Years · Female only"
      },
      "enrollment_count": 77,
      "start_date": "2016-04",
      "completion_date": "2018-07",
      "has_results": false,
      "last_update_posted_date": "2018-09-17",
      "last_synced_at": "2026-11-19T07:01:13.836Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03017170"
    },
    {
      "nct_id": "NCT00892450",
      "title": "Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Parkinson's Disease",
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "Oxybutynin and darifenacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 12,
      "start_date": "2009-05",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2014-10-03",
      "last_synced_at": "2026-11-19T07:01:13.836Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00892450"
    },
    {
      "nct_id": "NCT03755089",
      "title": "Oral vs Intravesical Analgesia for Office Bladder Botox Injections",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Overactive Bladder Syndrome",
        "Urge Incontinence",
        "Urinary Incontinence",
        "Detrusor Hyperreflexia",
        "Detrusor Instability"
      ],
      "interventions": [
        {
          "name": "Phenazopyridine",
          "type": "DRUG"
        },
        {
          "name": "Lidocaine 2% Injectable Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Women and Infants Hospital of Rhode Island",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 99 Years · Female only"
      },
      "enrollment_count": 110,
      "start_date": "2018-11-01",
      "completion_date": "2021-03-01",
      "has_results": false,
      "last_update_posted_date": "2020-05-29",
      "last_synced_at": "2026-11-19T07:01:13.836Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03755089"
    },
    {
      "nct_id": "NCT00584090",
      "title": "Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Urinary Incontinence",
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Solifenacin Succinate (VESIcare)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2007-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-12-03",
      "last_synced_at": "2026-11-19T07:01:13.836Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00584090"
    },
    {
      "nct_id": "NCT03104517",
      "title": "Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stress Urinary Incontinence"
      ],
      "interventions": [
        {
          "name": "AMDC-USR (iltamiocel)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Cook MyoSite",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 96,
      "start_date": "2019-04-23",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-11-19T07:01:13.836Z",
      "location_count": 20,
      "location_summary": "Tucson, Arizona • La Mesa, California • Los Angeles, California + 17 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Westlake Village",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03104517"
    },
    {
      "nct_id": "NCT00922740",
      "title": "VA106483 Dose Response Study in Elderly Males",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Nocturia"
      ],
      "interventions": [
        {
          "name": "VA106483",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vantia Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "65 Years and older · Male only"
      },
      "enrollment_count": 10,
      "start_date": "2009-06",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2018-05-23",
      "last_synced_at": "2026-11-19T07:01:13.836Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00922740"
    }
  ]
}